Rondecabtagene autoleucel
Cell therapy
Evidence outlook · registrational
Large B-Cell Lymphoma: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2029-12.
Company guidance: topline data expected mid-2027 (NCT05826535; Lyell Immunopharma, Inc., 6 Aug 2026). “Additional data from this trial are expected in the second half of 2026, and pivotal data are expected in mid-2027” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
PiNACLE-H2H NCT07188558 · Large B-Cell Lymphoma Registry: NCT07188558 | 3 | Event free survival (36 months) 2029-12 | In progress: results expected 1 Dec 2029 | not yet graded | link ↗ |
View 1 more trial
NCT05826535 NCT05826535 · Large B-Cell Lymphoma Registry: NCT05826535 | 1/2 | Phase 1: Evaluate the safety and tolerability of a single dose of ronde-cel administered as a single agent (Baseline to Month 24); Phase 2: Estimate the efficacy of ronde-cel, as measured by overall response rate (ORR) (Baseline to Month 24) 2028-12-31 | In progress: results expected 31 Dec 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
This drug's own stage for Large B-Cell Lymphoma: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Rondecabtagene Autoleucel: this drug | Phase 3 | Cell therapy | CD19 / CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Brentuximab Vedotin | Approved | Antibody–drug conjugate | Anti-CD30 antibody-drug conjugate | not yet graded | No reviewed efficacy summary in this indication | |
| Epcoritamab | Approved | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| PF-05280586 | Approved | Biologic (subtype unspecified) | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Tafasitamab | Approved | Monoclonal antibody | CD19 | Weak signal | NCT02399085: Number of Participants With Best Objective Response Rate (ORR) (Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled): Treatment (MOR00208, Lenalidomide) — Approximately 4.5 years after first participant enrolled: 46 Participants; Approximately 6.5 years after first participant enrolled: 46 Participants | |
| Golcadomide | Phase 3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Surovatamig | Phase 3 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Cemacabtagene Ansegedleucel | Phase 2 | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Rondecabtagene autoleucel to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
December 2028 (1)
Company guidance: topline data expected mid-2027 (Lyell Immunopharma, Inc., 6 Aug 2026). “Additional data from this trial are expected in the second half of 2026, and pivotal data are expected in mid-2027” Source ↗